BioCryst Pharmaceuticals (NASDAQ:BCRX) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX - Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. They currently have a $30.00 price target on the biotechnology company's stock.

Separately, Needham & Company LLC reiterated a buy rating and issued a $12.00 price objective on shares of BioCryst Pharmaceuticals in a report on Wednesday, April 10th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus price target of $14.00.

BioCryst Pharmaceuticals Stock Down 0.2 %

NASDAQ:BCRX traded down $0.01 on Tuesday, reaching $5.26. The company's stock had a trading volume of 6,214,087 shares, compared to its average volume of 3,395,612. BioCryst Pharmaceuticals has a 12-month low of $4.03 and a 12-month high of $8.96. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of -4.46 and a beta of 1.96. The stock has a 50 day moving average price of $4.92 and a 200 day moving average price of $5.46.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its earnings results on Monday, May 6th. The biotechnology company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.06. The business had revenue of $92.80 million during the quarter, compared to analysts' expectations of $85.62 million. During the same quarter in the prior year, the firm earned ($0.28) EPS. BioCryst Pharmaceuticals's revenue for the quarter was up 34.9% compared to the same quarter last year. Equities research analysts expect that BioCryst Pharmaceuticals will post -0.69 EPS for the current fiscal year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Large investors have recently bought and sold shares of the stock. Fifth Third Bancorp increased its holdings in BioCryst Pharmaceuticals by 17,500.0% during the 3rd quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company's stock worth $25,000 after purchasing an additional 3,500 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of BioCryst Pharmaceuticals by 96.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company's stock worth $34,000 after acquiring an additional 2,388 shares in the last quarter. Quarry LP acquired a new position in shares of BioCryst Pharmaceuticals during the 4th quarter worth about $54,000. Tower Research Capital LLC TRC boosted its position in shares of BioCryst Pharmaceuticals by 131.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,420 shares of the biotechnology company's stock worth $62,000 after acquiring an additional 5,912 shares in the last quarter. Finally, JGP Global Gestao de Recursos Ltda. acquired a new position in shares of BioCryst Pharmaceuticals during the 4th quarter worth about $64,000. Hedge funds and other institutional investors own 85.88% of the company's stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.